GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolys BioPharma Inc (TSE:4588) » Definitions » Shiller PE Ratio

Oncolys BioPharma (TSE:4588) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Oncolys BioPharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncolys BioPharma Shiller PE Ratio Historical Data

The historical data trend for Oncolys BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolys BioPharma Shiller PE Ratio Chart

Oncolys BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolys BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncolys BioPharma's Shiller PE Ratio

For the Biotechnology subindustry, Oncolys BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolys BioPharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncolys BioPharma's Shiller PE Ratio falls into.



Oncolys BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oncolys BioPharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Oncolys BioPharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-18.24/107.2000*107.2000
=-18.240

Current CPI (Mar. 2024) = 107.2000.

Oncolys BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -19.730 98.000 -21.582
201409 -17.450 98.500 -18.991
201412 -31.820 97.900 -34.843
201503 -22.290 97.900 -24.407
201506 -21.976 98.400 -23.941
201509 -21.200 98.500 -23.072
201512 -27.893 98.100 -30.480
201603 -20.280 97.900 -22.206
201606 -25.230 98.100 -27.570
201609 -34.020 98.000 -37.214
201612 -21.650 98.400 -23.586
201703 -25.910 98.100 -28.313
201706 -27.980 98.500 -30.451
201709 -23.920 98.800 -25.954
201712 -28.420 99.400 -30.650
201803 -28.090 99.200 -30.355
201806 -29.807 99.200 -32.211
201809 -21.420 99.900 -22.985
201812 -25.240 99.700 -27.139
201903 -26.910 99.700 -28.934
201906 6.104 99.800 6.557
201909 -22.660 100.100 -24.267
201912 -22.820 100.500 -24.341
202003 -19.960 100.300 -21.333
202006 -26.470 99.900 -28.404
202009 -61.210 99.900 -65.683
202012 -37.940 99.300 -40.958
202103 -22.360 99.900 -23.994
202106 -17.332 99.500 -18.673
202109 -18.978 100.100 -20.324
202112 -37.080 100.100 -39.710
202203 -18.980 101.100 -20.125
202206 -13.940 101.800 -14.679
202209 -15.280 103.100 -15.888
202212 -18.110 104.100 -18.649
202303 -18.690 104.400 -19.191
202306 -31.470 105.200 -32.068
202309 -22.990 106.200 -23.206
202312 -35.770 106.800 -35.904
202403 -18.240 107.200 -18.240

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncolys BioPharma  (TSE:4588) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oncolys BioPharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oncolys BioPharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolys BioPharma (TSE:4588) Business Description

Traded in Other Exchanges
N/A
Address
4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is engaged in research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agents.

Oncolys BioPharma (TSE:4588) Headlines

No Headlines